245
Participants
Start Date
January 23, 2019
Primary Completion Date
January 8, 2021
Study Completion Date
December 20, 2021
Canakinumab
Canakinumab, 200 mg, subcutaneous. The initial dose regimen was once every 3 weeks (on Day 1 of each 21-day cycle)
Docetaxel
Docetaxel 75mg/m\^2, intravenous, administered on Day 1 of each 21-day cycle
Placebo
Placebo, sub-cutaneous, admnistered at the RP3R defined in Part 1-safety run-in.
Novartis Investigative Site, Brussels
Novartis Investigative Site, Törökbálint
Novartis Investigative Site, Shepparton
Novartis Investigative Site, Greenslopes
Novartis Investigative Site, Santiago del Estero
Novartis Investigative Site, La Rioja
Novartis Investigative Site, Charleroi
Novartis Investigative Site, Roeselare
Novartis Investigative Site, Ghent
Novartis Investigative Site, Sint-Niklaas
Montefiore Medical Center Albert Einstein College of Med, The Bronx
Novartis Investigative Site, Amman
Novartis Investigative Site, Berlin
Novartis Investigative Site, A Coruña
Novartis Investigative Site, Rozzano
Novartis Investigative Site, Großhansdorf
Novartis Investigative Site, Besançon
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Málaga
Emory Winship Cancer Institute, Atlanta
Novartis Investigative Site, Bordeaux
Novartis Investigative Site, Aviano
University of Cincinnati Cancer Institute, Cincinnati
Novartis Investigative Site, Valencia
Novartis Investigative Site, Cologne
Novartis Investigative Site, Ramat Gan
Novartis Investigative Site, Lucca
Novartis Investigative Site, Thessaloniki
Novartis Investigative Site, Frankfurt
Saint Luke's Hospital/Marion Bloch Neuroscience Institute Dept of Regulatory, Kansas City
Novartis Investigative Site, Strasbourg
Novartis Investigative Site, Bron
Novartis Investigative Site, Tainan City
Novartis Investigative Site, Gerlingen
Novartis Investigative Site, Le Mans
MD Anderson, Houston
Novartis Investigative Site, Ulm
Novartis Investigative Site, Taipei
Novartis Investigative Site, El Achrafiyé
Novartis Investigative Site, Singapore
Novartis Investigative Site, Pushkin Saint Petersburg
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Chengdu
Novartis Investigative Site, Santiago
Huntsman Cancer Institute Univ of Utah ., Salt Lake City
Novartis Investigative Site, Berazategui
Novartis Investigative Site, CABA
Novartis Investigative Site, Mar del Plata
Novartis Investigative Site, Salvador
Novartis Investigative Site, Porto Alegre
Novartis Investigative Site, Itajaí
Novartis Investigative Site, Vancouver
Novartis Investigative Site, Montreal
Novartis Investigative Site, Brno - Bohunice
Novartis Investigative Site, Ostrava Vitkovice
Novartis Investigative Site, Herlev
Novartis Investigative Site, Odense C
Novartis Investigative Site, Dresden
Novartis Investigative Site, Heraklion Crete
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Himeji
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Chuo Ku
Novartis Investigative Site, Osaka
Novartis Investigative Site, Amsterdam
Novartis Investigative Site, Groningen
Novartis Investigative Site, Maastricht
Novartis Investigative Site, Gdansk
Novartis Investigative Site, Rzeszów
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Badalona
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY